Product Nature:

Trelagliptin succinate is the world's first weekly oral DPP 4 inhibitors, used in type 2 diabetes, this product is a weekly dipeptide base peptidase IV (DPP - 4) inhibitors, through selective, sustained suppression DPP - 4, control blood sugar levels. glucose dependence polypeptide (GIP) inactivation, and these two im down an important role in regulating blood sugar. Inhibiting dd-4 can increase blood glucose levels dependent on secretion, which can control blood glucose levels.

Specification Description:
Trelagliptin is a weekly dipeptidyl peptidase IV (DPP-4) inhibitor that controls blood glucose levels by selectively and persistently inhibiting DPP-4. Dpp-4 is an enzyme that induces the inactivation of incretin (glucagon-glucagon-like peptides-1 (GLP-1) and glucose-dependent incretin (GIP), which play an important role in blood glucose regulation. Inhibition of DPP-4 can increase the secretion of  dependent on blood glucose level, thus controlling blood glucose level.
Tragliptin succinate is a white to quasi-white crystalline or crystalline powder, soluble in water or dimethyl sulphoxide, slightly soluble in , slightly soluble in ethanol (99.5),  or , and very slightly dissolved in  or 

Function:

Triagliptin succinate is a dipeptidyl peptidase -IV,DPP- IV) inhibitor developed by Takeda(Takeda Pharmaceutical Co., LTD.) in Japan. It can selectively and persistently inhibit DPP- IV and control blood glucose level. Clinical trials of Chemicalbook show that the drug has a good safety and efficacy, and can effectively control blood glucose levels and improve medication compliance in patients when administered once a week. In May 2015, the drug was approved by PMDA in Japan for the treatment of diabetes.